Sadik Abdulwehab – Infectious Diseases Prevention – Best Researcher Award

Posted on by Infectious

Sadik Abdulwehab - Infectious Diseases Prevention - Best Researcher Award

Wollega University,Nekemte,Ethiopia - Ethiopia

AUTHOR PROFILE 

ORCID

EARLY ACADEMIC PURSUITS 🎓

Sadik Abdulwehab Wake’s academic journey began in Ethiopia, where he cultivated a solid foundation for his future in health sciences. After attending Oda Dannisa Elementary School and Digalu Secondary School, he continued to Sagure Preparatory School. With a commitment to public health and community well-being, Sadik earned his Bachelor of Science in Nursing from Wollega University in 2017, graduating with distinction. Driven by a strong desire to contribute meaningfully to healthcare systems, he pursued and completed a Master of Science in Adult Health Nursing from Jimma University in 2024, further sharpening his expertise. His academic performance consistently demonstrated excellence, with GPAs of 3.94 and 3.92, respectively. Throughout his education, Sadik showed a keen interest in addressing national and global health priorities such as Infectious Diseases Prevention. His passion for evidence-based practice, patient autonomy, and chronic disease care was cultivated during this period, laying the groundwork for impactful contributions. His graduate studies emphasized clinical reasoning, public health strategies, and advanced nursing practice, reinforcing his commitment to Infectious Diseases Prevention. These formative years reflect a powerful alignment between academic rigor and a mission to reduce the burden of infectious diseases, particularly in underserved populations where health literacy and resource gaps remain profound challenges.

PROFESSIONAL ENDEAVORS 🏥

Sadik Abdulwehab Wake began his professional career as a clinical nurse at Nedjo General Hospital from 2018 to 2020, where he played a crucial role in direct patient care, collaborative treatment planning, and community health engagement. His frontline experience offered invaluable insights into the realities of healthcare delivery in Ethiopia, especially concerning chronic illness management and Infectious Diseases Prevention. Transitioning to academia in 2020, he took up a lecturer position at Wollega University. There, he actively contributed to curriculum development, clinical instruction, and undergraduate research mentoring. His academic setting allowed him to emphasize the principles of Infectious Diseases Prevention through student training, seminars, and collaborative projects. He promoted evidence-based approaches to nursing, often incorporating practical applications from his clinical experiences. His dual role as educator and practitioner bridged the gap between theory and real-world application, particularly in the areas of adult health and infectious disease control. Sadik consistently used his platform to advocate for stronger health systems, capacity-building, and the inclusion of Infectious Diseases Prevention as a standard pillar of nursing education. His leadership in academia reflects a commitment not only to teaching but also to nurturing the next generation of health professionals dedicated to public health improvement.

RESEARCH AND SCHOLARLY CONTRIBUTIONS 🔬

Sadik Abdulwehab Wake has built an impressive portfolio of research focused on systemic healthcare challenges, with a continuous emphasis on Infectious Diseases Prevention. His published studies include a landmark meta-analysis on workplace violence against nurses in Ethiopia and multiple articles addressing patient autonomy, stroke outcomes, erectile dysfunction among diabetics, and asthma management. A recurring theme in his work is the intersection between chronic illness and infection control, showcasing his concern for how underlying diseases complicate Infectious Diseases Prevention efforts. He has authored and co-authored more than a dozen studies, many of which are featured in respected international journals such as BMC Nursing, Clinical Epidemiology and Global Health, and Frontiers in Allergy. His ongoing investigations further explore topics like antiretroviral therapy adherence, palliative care access, and barriers to diabetes self-care—each with implications for reducing infection vulnerability. His work reflects both a scientific and humanitarian mission, aiming to transform healthcare delivery for marginalized populations. Sadik’s use of meta-analysis and qualitative reviews demonstrates methodological rigor, while his thematic focus on Infectious Diseases Prevention addresses a critical area of global concern. Through research, he not only generates knowledge but also advocates for policy changes and health practices that protect at-risk groups.

AWARDS AND RECOGNITION 🏆

Though still in the early stages of his academic and research career, Sadik Abdulwehab Wake has already garnered substantial recognition for his contributions to nursing and Infectious Diseases Prevention. Graduating with top academic honors from both Wollega and Jimma University, he has consistently demonstrated a high level of excellence and integrity. His systematic reviews and meta-analyses are frequently cited in the context of health system evaluations and chronic disease management. While formal national or international awards are still forthcoming, Sadik’s growing citation index, successful collaborations, and respected standing among peers underscore his rising influence in Ethiopian academic circles. His research leadership on pressing public health topics—particularly those intersecting with Infectious Diseases Prevention—has also earned him invitations to contribute to collaborative studies and review boards. He is frequently sought after for mentorship roles, particularly by younger nursing scholars pursuing studies related to cancer care, HIV/AIDS, and diabetes-related infections. Sadik’s consistent involvement in high-impact research reflects his ability to translate academic knowledge into practical change. His trajectory promises future accolades as his work continues to shape how nursing responds to infectious disease threats in resource-limited settings, with his expertise contributing meaningfully to national and global health resilience.

IMPACT AND INFLUENCE 🌍

Sadik Abdulwehab Wake’s impact extends beyond the classroom and the research lab, reaching into the communities most affected by poor healthcare access and infectious disease burdens. By promoting Infectious Diseases Prevention through education, advocacy, and scientific inquiry, he has become a catalyst for change within both academic and clinical settings. His efforts have enhanced awareness of the challenges nurses face on the ground, especially in sub-Saharan Africa, where the overlap of chronic conditions and infectious diseases is particularly deadly. Through his research on patient autonomy and healthcare decision-making, he empowers patients and families to take active roles in managing conditions while reducing preventable infections. Sadik’s lectures integrate global nursing perspectives, allowing students to see their local work as part of a broader fight for health equity. He frequently contributes to university forums, policy discussions, and regional conferences where Infectious Diseases Prevention is a key topic. Furthermore, his collaboration with colleagues from Jimma and Wollega University has seeded multi-institutional research projects aimed at tackling critical health disparities. Sadik’s influence is steadily growing as he connects his academic rigor with real-world health solutions, ensuring that evidence-based nursing contributes to safer, healthier communities throughout Ethiopia and beyond.

LEGACY AND FUTURE CONTRIBUTIONS 🔮

Looking ahead, Sadik Abdulwehab Wake envisions a future where Infectious Diseases Prevention becomes fully integrated into all aspects of nursing education, practice, and policy. His long-term goals include launching interdisciplinary training programs that equip nurses with tools to address emerging infectious threats and chronic disease burdens simultaneously. He is also working to expand his publication footprint through international collaborations, aiming to bring Ethiopian perspectives into global health discussions. Sadik plans to initiate community-based intervention studies, especially targeting vulnerable populations affected by HIV/AIDS, diabetes, and cancer, where secondary infections are prevalent. His dedication to mentorship remains a core part of his legacy; by guiding new nursing scholars, he ensures continuity in advancing research, ethics, and Infectious Diseases Prevention. He is particularly interested in exploring the role of telehealth and digital tools in managing infections in remote areas, bridging care gaps where infrastructure is limited. As a passionate advocate for health equity, Sadik’s future contributions will focus on policy recommendations that support sustainable health improvements. His legacy will be defined by the lives he uplifts, the systems he strengthens, and the persistent voice he raises for Infectious Diseases Prevention in both local and international spheres.

NOTABLE PUBLICATION

  • Title: Deep vein thrombosis in Ethiopia: a systematic review and meta-analysis
    Authors: Sadik Abdulwehab; Frezer Kedir
    Journal: Thrombosis Journal

  • Title: Prehospital delay and associated factors among stroke patients in Africa: A systematic review and meta-analysis
    Authors: Duguma Debela Ganeti; Ilker Kacer; Amanuel Oljira Dulo; Birhanu Wogane Ilala; Nuritu Bacha Benti; Misganu Diriba; Sadik Abdulwehab; Diriba Etana Tola; Lencho Kajela Solbana
    Journal: PLOS One

  • Title: Workplace violence against nurse: a systematic review and meta-analysis in Ethiopia
    Authors: Sadik Abdulwehab; Frezer Kedir
    Journal: BMC Nursing

  • Title: Engagement in healthcare decision-making and associated factors among patients with chronic non-communicable diseases in Southwest Ethiopia, 2023
    Authors: Sadik Abdulwehab; Yeshitila Belay; Frezer Kedir; Ebrahim Yimam; Admasu Belay
    Journal: Clinical Epidemiology and Global Health

  • Title: Patient autonomy in self-managing their bronchial asthma exacerbation and its associated factors
    Authors: Sadik Abdulwehab; Frezer Kedir
    Journal: Frontiers in Allergy

Kouichi Asahi – Fungal Infections – Excellence in Innovation

Posted on by Infectious

Kouichi Asahi - Fungal Infections - Excellence in Innovation

Dokkyo Medical Univiersity Saitama Medical Center - Japan

AUTHOR PROFILE 

ORCID

EARLY JOURNEY IN MEDICAL SCIENCE 🧬

Dr. Kouichi Asahi began his academic journey with a passion for the fundamentals of clinical medicine and a keen interest in diagnostic precision. Earning his M.D. from a prestigious Japanese medical school, he went on to gain board certifications in Internal Medicine, Radiology, and General Practice. From early in his training, Dr. Asahi demonstrated a strong inclination toward the complexities of infectious diseases, especially Fungal Infections. His education laid the foundation for a multidisciplinary approach to diagnosis and care, integrating radiological interpretation with frontline clinical medicine. Dr. Asahi’s academic interests soon gravitated toward how imaging can unearth elusive conditions like invasive Fungal Infections, often misdiagnosed or underrecognized. These challenges inspired him to pursue investigative approaches to the intersection of radiology and mycology. His early academic mentors recognized his deep curiosity and precise analytical thinking—traits that propelled him into complex case studies and rare disease presentations. Throughout his formative years, he participated in research and case evaluations that involved Fungal Infections, helping to establish his long-term commitment to this niche but vital area. These early pursuits cultivated a dedication that would evolve into an influential role in understanding and treating Fungal Infections across clinical domains.

CLINICAL PRACTICE AND RESPONSIBILITY ⚕️

In his dual roles as Vice Director at Kohokuekimae Ohisama Clinic and Attending Physician at Dokkyo Medical University Saitama Medical Center, Dr. Kouichi Asahi exemplifies dedication to patient-centered care. With over a decade of clinical involvement, he has steadily expanded his reach within general medicine and radiology. His practice routinely addresses infectious diseases, with a special emphasis on elusive diagnoses such as Fungal Infections. At the hospital and the community clinic alike, Dr. Asahi is known for methodically identifying complicated cases involving Fungal Infections that mimic other illnesses. He leverages his radiological expertise to pinpoint these infections, often before overt clinical symptoms appear. His daily responsibilities include not only treating patients but also mentoring young clinicians in diagnosing Fungal Infections more accurately. His approach is multidisciplinary, incorporating traditional Japanese Kampo medicine alongside modern therapeutics to manage complex cases. Dr. Asahi’s leadership extends beyond treatment—he is instrumental in guiding protocols for early detection of Fungal Infections, particularly in immunocompromised individuals. His holistic care model bridges technology, tradition, and patient empathy, reinforcing his belief that every medical mystery—especially Fungal Infections—deserves both scientific and humanistic attention. Through his practice, Dr. Asahi continuously enhances awareness and response strategies for Fungal Infections within Japan’s healthcare system.

RESEARCH ON DIAGNOSTIC CHALLENGES 🔬

Dr. Kouichi Asahi’s research trajectory is deeply rooted in solving diagnostic conundrums, especially in the realm of Fungal Infections. His landmark case report on invasive aspergillosis with intracranial extension showcases his acumen in detecting rare fungal pathologies often mistaken for other diseases. This study not only highlighted the complexities of neuroinvasive Fungal Infections but also addressed the common diagnostic pitfalls encountered in internal medicine and radiology. Dr. Asahi uses neuroimaging techniques to distinguish fungal etiologies from granulomatous or neoplastic lesions, making significant contributions to the growing field of radiological mycology. His research draws attention to how subtle radiologic signs can drastically alter treatment outcomes when Fungal Infections are correctly identified. Through his academic work, he encourages the reevaluation of diagnostic frameworks that often overlook fungal etiologies. He also integrates elements of Kampo medicine in research hypotheses, investigating potential synergy between traditional remedies and antifungal strategies. His passion for diagnostic clarity has driven him to publish in reputable journals like J. Fungi, where his findings have influenced both clinical awareness and research directions. Fungal Infections remain central to his investigative endeavors, guiding his efforts to enhance early detection and improve therapeutic accuracy in complex infectious scenarios.

ACADEMIC CONTRIBUTIONS AND PUBLICATIONS 📚

Dr. Asahi’s contributions to medical literature are both precise and impactful, particularly in the study of Fungal Infections. His publication on invasive aspergillosis brought to light a clinically misdiagnosed condition, demonstrating his talent for unraveling subtle but significant clinical narratives. This report emphasized the diagnostic hurdles surrounding Fungal Infections with neurological manifestations and has since been cited as a reference for similar complex cases. Beyond case reporting, Dr. Asahi is deeply involved in academic discussions around imaging interpretation and its role in diagnosing Fungal Infections across different organ systems. His dual expertise in internal medicine and radiology uniquely positions him to present nuanced insights that bridge two critical diagnostic disciplines. He actively contributes to conferences on infectious diseases, where his case studies and imaging interpretations have prompted dialogue on refining fungal diagnostic criteria. His work is not limited to academic journals; he mentors students and residents in clinical research, guiding them in investigating underrepresented infectious cases, particularly Fungal Infections. By transforming clinical experiences into publishable academic material, Dr. Asahi ensures that valuable insights on Fungal Infections reach the wider medical community, contributing to better patient outcomes and enhanced physician awareness worldwide.

INNOVATION IN CLINICAL APPROACHES 💡

Innovation defines Dr. Kouichi Asahi’s methodology in tackling infectious diseases, especially Fungal Infections. He advocates for an integrated diagnostic approach, combining imaging, laboratory findings, and traditional medicine for early identification and personalized treatment of Fungal Infections. Dr. Asahi is a pioneer in incorporating Kampo medicine—Japan’s traditional medical system—with modern pharmacology to enhance treatment outcomes in complex fungal cases. His innovations also extend to protocol development, where he has led initiatives to standardize diagnostic pathways for Fungal Infections in general practice settings. These protocols assist clinicians in recognizing non-specific symptoms that may hint at deep-seated fungal etiologies. His imaging innovations include refined criteria for interpreting CT and MRI scans in the context of suspected Fungal Infections, particularly of the brain and lungs. By aligning technological advancements with traditional diagnostic wisdom, Dr. Asahi has developed a hybrid framework that increases diagnostic confidence. His unique perspective encourages a departure from overly compartmentalized medicine, advocating instead for a systems-based approach to Fungal Infections. His contributions have shaped institutional practices and inspired interdisciplinary collaboration, all rooted in his ongoing commitment to improving outcomes for patients affected by Fungal Infections.

RECOGNITION AND GLOBAL IMPACT 🌍

Dr. Kouichi Asahi’s clinical insight and research excellence have earned him recognition on international platforms. A candidate for the 2025 International Research Awards on Infectious Diseases, Dr. Asahi has distinguished himself through groundbreaking work on Fungal Infections. His research, case presentations, and advocacy have resonated with a global audience seeking advanced diagnostic and therapeutic strategies in mycology. His influence reaches beyond Japan, as he collaborates with international experts in refining protocols for the early detection and management of Fungal Infections. His role as a public relations officer at his clinic also allows him to disseminate essential health information on infectious diseases, including fungal risks, to broader communities. His ability to communicate scientific complexities in accessible language helps bridge gaps between clinical research and public understanding. Dr. Asahi’s recognition extends to his mentorship of junior physicians, whom he trains to consider Fungal Infections more readily in differential diagnoses. His global footprint is not only built on academic merit but also on the meaningful, life-saving impact of his work in the real world. Through teaching, publishing, and innovating, Dr. Asahi continues to redefine how the medical community approaches and responds to Fungal Infections.

FUTURE OUTLOOK AND LEGACY VISION 🔮

Looking ahead, Dr. Kouichi Asahi envisions a healthcare landscape where Fungal Infections are promptly recognized, accurately diagnosed, and effectively treated using interdisciplinary tools. His legacy lies not only in his contributions to diagnostic radiology and internal medicine but also in his consistent focus on Fungal Infections as a growing global concern. He aims to establish a dedicated center for fungal diagnostics in Japan, where imaging technology, laboratory analysis, and traditional medicine converge. Dr. Asahi is also advocating for curriculum revisions in medical schools to include deeper instruction on Fungal Infections, recognizing the gap in awareness among upcoming clinicians. His long-term goals include producing educational resources—both digital and print—that focus on the nuances of identifying and managing fungal diseases. As his mentorship influence grows, so too does his impact on shaping a new generation of clinicians attuned to the complexities of Fungal Infections. Through a career defined by clinical precision, research integrity, and compassionate care, Dr. Asahi is building a legacy that will elevate the global response to fungal threats. His dedication ensures that Fungal Infections remain a medical priority, not just an academic curiosity.

NOTABLE PUBLICATION 

  • Title: Invasive Aspergillosis with Intracranial Extension Initially Misdiagnosed as a Granulomatous Disease: A Case Report
    Author: Kouichi Asahi
    Journal: Journal of Fungi

  • Title: A Case of Refractory Hiccups and Numbness as the Initial Presentation of Multiple Sclerosis
    Author: Kouichi Asahi
    Journal: Cureus

  • Title: Splenic injury with right rib fractures
    Authors: Kouichi Asahi, Jitsuiki K, Takeuchi I, Yoshizawa T, Ishikawa K, Kazuhiko Omori, Hiromichi Ohsaka, Oode Y, Youichi Yanagawa
    Journal: Scholars Journal of Medical Case Reports

  • Title: MR Imaging for Sportology; Non-Invasive Visualization of the Brain and Muscles
    Authors: Shigeki Aoki, Masaaki Hori, Atsushi Nakanishi, Christina Andica, Misaki Nakazawa, Kanako Sato, Kouichi Asahi, Keigo Shimoji
    Journal: Juntendo Medical Journal

  • Title: Transcatheter Arterial Coil Embolization of Ruptured Common Hepatic Artery Aneurysm in a Patient with Behçet’s Disease
    Authors: Akihiro Hotta, Ryohei Kuwatsuru, Kouichi Asahi, Shingo Okada, Daisuke Tsuge, Akihiko Shiraishi, Yoshinari Takasaki
    Journal: Case Reports in Radiology

Ademola Aiyenuro – Pathology – Best Research Article Award

Posted on by Infectious

Ademola Aiyenuro - Pathology - Best Research Article Award

University of Cambridge - United Kingdom

AUTHOR PROFILE 

GOOGLE SCHOLAR

ACADEMIC ROOTS & RISING AMBITIONS 🎓

Ademola Emmanuel Aiyenuro’s academic journey is deeply rooted in excellence and a passion for Pathology. After achieving First Class Honours in Microbiology from the Federal University of Technology, Akure, Nigeria, his quest for specialized knowledge led him to the University of Cambridge. There, he pursued an MPhil in Pathology, supported by the HRH Prince of Wales Cambridge Trust Scholarship. His dissertation focused on reserve cells in cervical neoplastic progression, laying the foundation for his later research in cervical cancer biology. Ademola’s dedication to Pathology became further pronounced during his PhD, also at Cambridge, where he focused on immune responses to HPV infections. His academic progress highlights a seamless blend of clinical microbiology, molecular diagnostics, and advanced immunopathological research. Through his training, Ademola mastered critical Pathology techniques like RNAscope, immunofluorescence, and tissue imaging. His understanding of Pathology has not only deepened his technical skills but also shaped his perspective on translational medicine and disease prevention. His strong academic foundations in Pathology continue to support his innovative research endeavors. Across all stages, from undergraduate distinction to doctoral research, Pathology has remained the cornerstone of his scientific evolution, defining both his intellectual identity and his future trajectory in global health research.

PROFESSIONAL ENDEAVORS IN PATHOLOGY 🧪

Ademola Emmanuel Aiyenuro’s professional path has been immersed in the practice of Pathology through a series of hands-on roles. As a PhD candidate in the Department of Pathology at the University of Cambridge, he explored how high-risk HPV types evade immune surveillance in the cervical transformation zone. Using advanced Pathology tools—such as multiplexed antibody panels, immunofluorescence, and confocal microscopy—he deciphered immune exclusion patterns and viral oncogene expression at the single-cell level. In parallel, Ademola contributed as a Research Assistant, analyzing histological samples to assess tissue-specific immune landscapes, further solidifying his expertise in diagnostic and investigative Pathology. Outside academia, his role as a Medical Laboratory Scientist at St. Kizito Clinic exposed him to diagnostic Pathology on the frontlines, conducting microbiological, biochemical, and haematological analyses in HIV and TB patients. These dual roles bridged experimental Pathology with real-world medical diagnostics. Ademola also consulted for MRL® Public Sector Consultants, integrating Pathology-based insights into broader health system reform across Nigeria. This unique fusion of academic and applied Pathology enables him to operate across laboratory research, public health consultancy, and molecular diagnostics. Whether within a Cambridge lab or a Nigerian clinic, Ademola’s commitment to Pathology guides his mission to translate science into patient-centered solutions.

RESEARCH INNOVATION & DISEASE PREVENTION 🔬

Ademola Emmanuel Aiyenuro’s contributions to biomedical science are anchored in his commitment to innovation within Pathology and its application to disease prevention. At the core of his PhD research lies a detailed investigation into cervical precancer recurrence in women living with HIV, employing state-of-the-art Pathology methods to uncover HPV immune evasion mechanisms. His research in Pathology not only identifies molecular drivers of disease but also provides practical frameworks for therapeutic targeting. His co-authored publications—including studies on reserve cells in HPV lesions—have advanced knowledge in viral Pathology and oncogenesis. Ademola’s work has also extended into infectious diseases, where he has contributed to image-based diagnostics for Mpox as a Visiting Researcher at NYU Grossman School of Medicine. In each role, Pathology serves as a diagnostic and prognostic lens through which he dissects disease processes at the cellular and molecular levels. He combines histological insights with computational data curation, ensuring that innovation in Pathology translates into real-world diagnostic improvements. Through literature reviews, grant writing, and peer-reviewed publishing, Ademola amplifies the relevance of Pathology in both academic and clinical discourse. His commitment to precision diagnostics underscores his vision of Pathology not as a static discipline, but as a dynamic engine for global health innovation.

IMPACTFUL ENGAGEMENT IN PUBLIC HEALTH 🌍

A central aspect of Ademola Emmanuel Aiyenuro’s journey has been his integration of Pathology with public health outreach. As a Public Health Officer at Loving Gaze, he spearheaded tuberculosis (TB) detection efforts under Nigeria’s national TB program, utilizing molecular diagnostics rooted in clinical Pathology. He performed GeneXpert testing to detect Mycobacterium tuberculosis and rifampicin resistance—translating Pathology-based diagnostics into high-impact interventions. His work was pivotal in monitoring treatment responses, managing toxicity, and evaluating outcomes using cohort analysis. Beyond diagnostics, Ademola led community-based case findings and health education programs, aligning Pathology-driven insights with behavioral and epidemiological strategies. At HealthDrive Nigeria, his role as a Board Member expanded his outreach by promoting Hepatitis B and C screening and vaccination in underserved communities. His ability to bridge Pathology with health policy and social impact reflects his holistic understanding of disease control. Whether through microscopy or molecular assays, Ademola’s public health initiatives have always returned to the foundational knowledge of Pathology. By linking tissue-level pathology with population-level interventions, he ensures that scientific findings do not remain confined to the lab but drive equitable healthcare access. His career epitomizes how Pathology, when thoughtfully applied, can become a tool for transformative social change.

ADVOCACY, EDUCATION & SCIENTIFIC COMMUNICATION 🗣️

Ademola Emmanuel Aiyenuro’s dedication to Pathology extends far beyond research—it fuels his passion for science education and advocacy. As an academic tutor at the Oxbridge Summer School, he introduced high school students to the fundamentals of genetics and biotechnology, laying early foundations in the life sciences and integrating key concepts from Pathology. In this role, Ademola emphasized the relevance of Pathology in understanding cellular processes and disease mechanisms, inspiring the next generation of biomedical scientists. Through his extensive academic writing and peer-reviewed publishing, Ademola has also become a dynamic science communicator. His publications, such as on HPV-related cervical pathology and COVID-19 diagnostics, have shaped discourse on viral pathogenesis and public health response. Media appearances on Channels TV and TVC News spotlighted his expertise in tuberculosis and malaria control, offering clear, accessible explanations rooted in clinical Pathology. Furthermore, his involvement with policy briefs and stakeholder engagement at MRL® showcases how his scientific communication shapes real-world reforms. Whether teaching young minds or addressing global audiences, Ademola remains a champion of using Pathology as a narrative tool—making science both engaging and empowering. Through his voice, Pathology resonates not only in labs and clinics but also in classrooms, boardrooms, and communities.

HONOURS, MEMBERSHIPS & RECOGNITION 🏅

Recognition of Ademola Emmanuel Aiyenuro’s work in Pathology is evidenced by his numerous awards and affiliations. As a recipient of the prestigious HRH Prince of Wales Cambridge Trust Commonwealth Scholarship, he demonstrated academic distinction in MPhil-level Pathology at Cambridge. His consistent academic excellence also earned him placement on the Dean’s List at the Federal University of Technology, Akure. These accolades underscore his longstanding dedication to Pathology and biomedical research. Ademola's active membership in top-tier professional societies—including the International Papillomavirus Society (IPVS), British Association for Cancer Research (BACR), British Society for Immunology (BSI), and American Society of Microbiology—highlights his global integration within the Pathology and infectious disease community. Through these platforms, he contributes to the advancement of virology, immunopathology, and cancer research. He is not only a participant but also a contributor to international scientific progress, with a voice that extends across symposia, academic publications, and policy frameworks. His awards and memberships affirm his impact, validating Pathology as both his field of specialization and a driver of cross-sectoral collaboration. These recognitions reflect his pursuit of excellence and continued contribution to the future of diagnostic and translational Pathology.

LEGACY & FUTURE DIRECTIONS IN PATHOLOGY 🚀

Ademola Emmanuel Aiyenuro’s vision for the future of Pathology is both ambitious and grounded in a commitment to health equity and scientific advancement. With his multidisciplinary background—spanning diagnostics, immunopathology, microbiology, and public health—he is poised to lead innovative projects that redefine how Pathology informs disease prevention and treatment. His current research on HPV immune control is just the beginning; his expertise positions him to contribute significantly to vaccine development, digital diagnostics, and global infectious disease monitoring. Ademola’s future work may explore the integration of artificial intelligence in histological analysis, expanding the possibilities of computational Pathology. He is also likely to remain active in policy advocacy, ensuring that evidence from Pathology labs informs equitable healthcare delivery, particularly in under-resourced settings like sub-Saharan Africa. Through continued collaboration with academic institutions, government bodies, and non-profit organizations, Ademola will shape a legacy that blends scientific rigor with social relevance. As he mentors young scientists and expands his influence, his contributions will continue to elevate the field of Pathology. His career embodies how focused research, when intertwined with purpose and empathy, can forge lasting impact. Pathology is not merely his specialization—it is his platform for transformative global health leadership.

NOTABLE PUBLICATION

  • Title: Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone
    Authors: J. Doorbar, K. Zheng, A. Aiyenuro, W. Yin, C.M. Walker, Y. Chen, N. Egawa, ...
    Journal: Current Opinion in Virology

 

  • Title: Immunoinformatics analysis to design novel epitope based vaccine candidate targeting the glycoprotein and nucleoprotein of Lassa mammarenavirus (LASMV) using strains from Nigeria
    Authors: O.A. Abass, V.I. Timofeev, B. Sarkar, D.O. Onobun, S.O. Ogunsola, ...
    Journal: Journal of Biomolecular Structure and Dynamics

 

  • Title: Experiences and projections for drug abuse sensitization and eradication among youths in South West, Nigeria
    Authors: S.O. Ogunsola, E.A. Fajemisin, A.E. Aiyenuro, A.A. Tunde
    Journal: Journal of Alcohol Drug Dependence Substance Abuse

 

  • Title: Antibacterial activity of sorghum “ogi” on diarrhoeagenic Escherichia coli
    Authors: T.T. Adebolu, D.V. Adediwura, E.A. Aiyenuro
    Journal: Journal of Advances in Microbiology

 

  • Title: Neglected Tropical Diseases (NTDs) and COVID-19 pandemic in Africa: Special focus on control strategies
    Authors: A.T. Aborode, E.A. Fajemisin, E.A. Aiyenuro, M.T. Alakitan, M.O. Ariwoola, ...
    Journal: Combinatorial Chemistry & High Throughput Screening

Filip Štrbac – Antibiotics – Best Researcher Award

Posted on by Infectious

Filip Štrbac - Antibiotics - Best Researcher Award

University of Belgrade - Institute for Multidisciplinary Research - Serbia

AUTHOR PROFILE 

ORCID
GOOGLE SCHOLAR

EARLY ACADEMIC ROOTS 🌱

Dr. Filip Štrbac’s academic journey in the field of veterinary medicine began with distinction and purpose. Born in Novi Sad, Serbia, his natural aptitude for science was evident during his time at “Jovan Jovanović Zmaj” High School, where he pursued natural sciences and mathematics. This foundation led him to the Faculty of Agriculture at the University of Novi Sad, where he enrolled in the integrated Veterinary Medicine program. Graduating with an impressive GPA of 9.58, his undergraduate thesis explored blood plasma proteins in poultry, showcasing an early interest in biochemistry and physiological processes, both of which intersect with the study of Antibiotics. His passion for veterinary pharmacology and parasitology only deepened as he advanced to doctoral studies. From 2017 to 2023, Dr. Štrbac conducted rigorous research on the anthelmintic efficacy of essential oils, a project intricately linked with the search for plant-based alternatives to conventional Antibiotics. His PhD thesis was not only a scientific contribution to parasitology but also a forward-looking effort to reduce reliance on synthetic Antibiotics in animal health. This pivotal work set the stage for his future investigations into Antibiotics resistance, phytotherapy, and sustainable veterinary interventions—issues central to both public and animal health in the 21st century.

RESEARCH PASSIONS IN VETERINARY SCIENCE 🔬

Dr. Filip Štrbac’s research career is anchored in a multidisciplinary exploration of parasitology, veterinary pharmacology, and phytotherapy—fields deeply connected with the current global discourse on Antibiotics. At the University of Novi Sad and later at the Institute for Multidisciplinary Research in Belgrade, his projects consistently addressed the challenge of Antibiotics resistance by exploring alternatives from nature, particularly essential oils with anthelmintic properties. His groundbreaking in vitro and in vivo studies on gastrointestinal nematodes in sheep examined the pharmacodynamics of plant-based compounds, providing comparative data with traditional Antibiotics. These investigations not only validated the efficacy of natural compounds but also contributed to understanding the mechanisms by which certain pathogens develop resistance to conventional Antibiotics. His collaborative work across European institutions, including research stays in Italy and Spain, enabled a cross-cultural scientific exchange on sustainable veterinary practices. Moreover, his leadership roles in international COST Actions, such as COMBAR and MedPlants4Vet, allowed him to advance studies on minimizing the ecological impact of synthetic Antibiotics. As a result, Dr. Štrbac’s work straddles the boundaries of pharmacology and ecology, advancing veterinary science while actively promoting a global reduction in the use of Antibiotics, thereby contributing to the worldwide effort to curb antimicrobial resistance.

CONTRIBUTIONS TO ANIMAL HEALTH AND THERAPEUTICS 🐑

One of Dr. Filip Štrbac’s most significant contributions lies in his innovative approaches to animal health care, specifically through the development of phytopharmacological strategies that reduce dependence on synthetic Antibiotics. His detailed work on essential oils such as peppermint, oregano, and winter savory demonstrated measurable anthelmintic effects against sheep gastrointestinal nematodes, offering a functional and ecologically safer alternative to traditional Antibiotics. With over ten influential publications in peer-reviewed journals, including Frontiers in Veterinary Science and BMC Veterinary Research, Dr. Štrbac has shaped the veterinary landscape toward sustainable therapeutics. These studies provided compelling evidence of how plant-derived compounds can serve as frontline agents against parasitic infections, particularly in livestock—a sector often overburdened with Antibiotics usage. His interdisciplinary methodology, combining in vitro assays, field trials, and pharmacological modeling, reflects a commitment to scientific rigor and real-world application. Furthermore, his active role in environmental projects such as ENVIRANT underscores his dedication to understanding how Antibiotics affect both treated animals and surrounding ecosystems. Dr. Štrbac’s holistic view of veterinary pharmacology—bridging animal welfare, environmental health, and microbial resistance—positions him as a leader in redefining therapeutic practices beyond conventional Antibiotics-based protocols in veterinary medicine.

GLOBAL COLLABORATIONS AND SCIENTIFIC NETWORKS 🌍

Dr. Filip Štrbac has strategically positioned himself within the global scientific community through active collaboration and leadership in numerous European research networks, focusing on sustainable solutions to challenges posed by overuse of Antibiotics. His work in the COST Actions—such as COMBAR, MedPlants4Vet, ENVIRANT, and BeSafeBeeHoney—has addressed the pressing issue of Antibiotics resistance in livestock systems. By engaging in these consortia, Dr. Štrbac contributed to developing regulatory frameworks and scientific roadmaps for integrating phytotherapeutic alternatives to conventional Antibiotics. His research stays in Spain and Italy, particularly at the University of Naples Federico II and the CREMOPAR Center, were instrumental in aligning Serbian veterinary research with broader EU standards. These exchanges enabled him to co-develop diagnostic protocols and efficacy tests for plant-based treatments in parasitic infections, targeting pathogens commonly treated with Antibiotics. Through these partnerships, he has been a vocal advocate for integrating traditional herbal knowledge with modern veterinary science, a philosophy increasingly seen as vital for reducing overreliance on Antibiotics globally. As an expert evaluator for COST project proposals and a reviewer for high-impact journals in pharmacology and veterinary medicine, he continues to influence how the international community approaches responsible Antibiotics usage, reinforcing a shift toward sustainable, evidence-based parasitic disease control.

SCHOLARSHIP, PUBLICATIONS, AND RECOGNITION 🏅

Dr. Filip Štrbac’s scholarly output reflects both depth and innovation, especially in the context of exploring non-conventional therapies as viable complements or substitutes for Antibiotics. With more than ten peer-reviewed publications focused on essential oils and their pharmacological efficacy, he has emerged as a recognized figure in phytotherapy and veterinary parasitology. His articles often appear in high-impact journals such as Frontiers in Veterinary Science, Veterinary Sciences, and Pakistan Veterinary Journal, where he compares plant-based anthelmintics to standard Antibiotics. The scope of his work includes ovicidal, larvicidal, and adulticidal activities of bioactive compounds, bringing new insights into sustainable parasite control. His excellence has been acknowledged through numerous academic honors, including the Best Student of Generation award and national PhD scholarships funded by the Serbian Ministry of Education. These accolades underscore his scholarly commitment and reflect his aim to address Antibiotics resistance in both national and international contexts. Moreover, his role as a reviewer for leading scientific journals and as an expert evaluator for COST proposals further solidifies his status as a thought leader on alternatives to Antibiotics. Each recognition he has received is a testament to his mission: to challenge traditional paradigms and advance veterinary therapeutics beyond the limits of Antibiotics.

IMPACT ON FUTURE VETERINARY PRACTICE 🚀

Dr. Filip Štrbac’s innovative work has set the foundation for a future in veterinary medicine where sustainability and precision replace dependency on conventional Antibiotics. His research not only expands the therapeutic arsenal with botanically derived anthelmintics but also introduces new frameworks for understanding the ecological implications of prolonged Antibiotics usage. His in vivo trials using essential oils such as oregano and peppermint highlight how natural compounds can achieve comparable or even superior efficacy to traditional Antibiotics without promoting microbial resistance. This groundbreaking evidence supports a paradigm shift in how veterinarians, farmers, and pharmaceutical developers approach parasite management. Through his involvement in multi-national EU projects like eco2adapt and INTACT, Dr. Štrbac promotes the integration of ecosystem-based adaptation into veterinary care, with a special emphasis on minimizing Antibiotics spillover into the environment. His work directly contributes to the One Health movement, bridging human, animal, and environmental health through the reduction of Antibiotics overuse. Future veterinary practitioners, researchers, and policy-makers stand to benefit immensely from the models, data, and strategies he is pioneering. In redefining therapeutic protocols through science-backed phytotherapy, Dr. Štrbac is reshaping the trajectory of global veterinary medicine away from over-reliance on Antibiotics and toward a resilient, sustainable future.

LEGACY AND VISION FOR ANTIBIOTICS ALTERNATIVES 🌿

Dr. Filip Štrbac’s legacy is already being etched into the evolving narrative of modern veterinary pharmacology, especially through his contributions to Antibiotics alternatives. By identifying and validating the therapeutic potential of essential oils and plant extracts, he champions a future where natural remedies complement or replace synthetic Antibiotics in combating parasitic diseases. His vision is deeply aligned with global initiatives targeting antimicrobial resistance, environmental sustainability, and holistic health. As the principal investigator in several international and national projects, Dr. Štrbac continuously advocates for bridging ethnopharmacological traditions with cutting-edge scientific validation. His comprehensive approach—spanning phytochemical analysis, in vivo trials, and regulatory integration—makes his work a blueprint for future Antibiotics research. Beyond his publications and laboratory contributions, his mentorship of young scientists and his engagement in science diplomacy position him as a transformative figure in veterinary medicine. His future goals include expanding phytotherapy databases, developing standardized protocols for plant-based treatments, and influencing policy for regulated, sustainable Antibiotics use. In essence, Dr. Štrbac’s enduring impact will be measured not only by the reduced reliance on Antibiotics but also by the healthier animals, ecosystems, and communities that benefit from his science-driven, nature-inspired approach to veterinary health.

NOTABLE PUBLICATION

  • Title: Anthelmintic resistance in gastrointestinal nematodes of sheep: Current situation and novel strategies
    Authors: Filip Štrbac, Dragica Stojanović
    Journal: Conference Paper – 2024, FeMeSPRumNS
  • Title: Physiological role, pharmacokinetics and pharmacodynamics of niacin in cows
    Authors: Kosta Petrović, Dragica Stojanović, Filip Štrbac, Talija Hristovska
    Journal: Conference Paper – 2024, FeMeSPRumNS
  • Title: Botanical Control of Parasites in Veterinary Medicine
    Authors: Filip Štrbac, Slobodan Krnjajić, Dragica Stojanović, Nikolina Novakov, Antonio Bosco, Nataša Simin, Radomir Ratajac, Slađan Stanković, Giuseppe Cringoli, Laura Rinaldi
    Journal: Book Chapter – One Health Triad, Vol. III, 2023
  • Title: In Vitro and In Vivo Anthelmintic Efficacy of Peppermint (Mentha x piperita L.) Essential Oil against Gastrointestinal Nematodes of Sheep
    Authors: Filip Štrbac, Slobodan Krnjajić, Dragica Stojanović, Radomir Ratajac, Nataša Simin, Dejan Orčić, Laura Rinaldi, Elena Ciccone, Maria Paola Maurelli, Giuseppe Cringoli et al.
    Journal: Frontiers in Veterinary Science – 2023-08-10
  • Title: A Potential Anthelmintic Phytopharmacological Source of Origanum vulgare (L.) Essential Oil against Gastrointestinal Nematodes of Sheep
    Authors: Filip Štrbac, Slobodan Krnjajić, Maria Paola Maurelli, Dragica Stojanović, Nataša Simin, Dejan Orčić, Radomir Ratajac, Kosta Petrović, Goran Knežević, Giuseppe Cringoli et al.
    Journal: Animals – 2022-12-22

Jinmin Ma – Hepatitis – Best Researcher Award

Posted on by Infectious

Jinmin Ma - Hepatitis - Best Researcher Award

BGI HuoYan Engineering - China

AUTHOR PROFILE

GOOGLE SCHOLAR

EARLY ACADEMIC JOURNEY 🎓

Dr. Jinmin Ma’s academic path laid a strong foundation for his lifelong commitment to advancing global health, particularly in the realm of Hepatitis research. He pursued his education in molecular biomedicine at the University of Copenhagen, Denmark, where he began delving into virology, pathogen-host interactions, and immune responses. His fascination with Hepatitis viruses—especially Hepatitis B and Hepatitis C—grew from these early investigations. Inspired by the burden of Hepatitis on public health worldwide, he focused on the molecular underpinnings of Hepatitis virus survival and replication. During his academic years, he engaged in numerous Hepatitis-related lab projects and developed specialized skills in RNA biology, viral pathogenesis, and molecular virology—all essential for understanding Hepatitis mechanisms. These academic pursuits enabled him to contribute early to the development of molecular detection tools for Hepatitis diagnosis. Even as a student, his drive to confront Hepatitis stood out, foreshadowing a prolific career centered on infectious diseases and Hepatitis. His thesis research on viral genomics offered valuable insight into the mutational patterns and gene expression shifts in Hepatitis. Today, his academic journey remains the cornerstone of his deep-seated expertise in Hepatitis virology. With Hepatitis driving his academic curiosity, Dr. Ma was set on a path to revolutionize the landscape of Hepatitis research.

INNOVATING THROUGH LEADERSHIP 🧬

Dr. Jinmin Ma’s transition from academic scholar to scientific leader marks a remarkable chapter in Hepatitis research. At BGI’s Infectious Disease Department, and later at HuoYan Engineering as Chief Technology Officer, he spearheaded multidisciplinary programs focusing on Hepatitis diagnostics, surveillance, and therapeutic strategies. Under his direction, high-throughput sequencing techniques were optimized to detect and characterize Hepatitis viruses with unprecedented accuracy. His leadership enabled the development of mRNA vaccine platforms targeting Hepatitis B, contributing to global strategies aimed at Hepatitis eradication. His professional milestones include managing grants from the Shenzhen Science and Technology Commission and the China Ministry of Science and Technology—many of which targeted Hepatitis prevention and personalized treatment. Dr. Ma also ensured that Hepatitis remained a top priority in infectious disease conferences and institutional research agendas. His stewardship fostered a dynamic research environment, integrating Hepatitis genomics, proteomics, and transcriptomics. By creating real-time molecular response systems for emerging Hepatitis outbreaks, he elevated public health responses. Dr. Ma’s leadership ensures that Hepatitis remains at the heart of institutional strategy, driving both national and international collaborations focused on Hepatitis control. His vision empowers new generations of researchers to keep Hepatitis prevention and treatment at the forefront of biomedical innovation.

RESEARCH AND DISCOVERY FRONTIERS 🔬

Dr. Jinmin Ma’s research on Hepatitis has significantly advanced our understanding of viral pathogenesis and host responses. His work encompasses over 80 publications, many centered on Hepatitis B and Hepatitis C virus biology. He was among the first to characterize genotype switching in Hepatitis B as a potential risk factor for vertical transmission. His studies revealed critical mechanisms by which Hepatitis viruses evade host immunity, contributing to chronic infection and liver damage. Through metagenomic sequencing and mRNA-based diagnostics, Dr. Ma has enhanced early detection strategies for Hepatitis, particularly in resource-limited settings. One of his landmark publications demonstrated how Hepatitis B virus (HBV) mutations affect viral persistence, adding depth to HBV evolutionary studies. His research also delved into transcriptomic profiling of Hepatitis-infected individuals, uncovering host immune suppression pathways. This led to the identification of novel biomarkers for disease staging and treatment efficacy. Dr. Ma has actively explored Hepatitis co-infections with other pathogens such as HIV and tuberculosis, assessing their synergistic effects on disease severity. He champions personalized medicine approaches tailored to Hepatitis genotypes and patient immune profiles. As Hepatitis remains a pressing global issue, Dr. Ma’s innovations continue to shape the future of Hepatitis diagnostics, therapeutics, and vaccine development.

IMPACT IN INFECTIOUS DISEASES 🌍

Few researchers have made such a comprehensive impact in infectious diseases as Dr. Jinmin Ma, especially in the context of Hepatitis. His scientific influence spans diverse domains—from molecular virology to public health policy—all unified by a central goal: to control and eliminate Hepatitis. He has played a vital role in reshaping national guidelines on Hepatitis surveillance through his integration of metatranscriptomic technologies. During the COVID-19 pandemic, he contributed to pandemic preparedness by applying Hepatitis research frameworks to RNA virus containment strategies. His tools for Hepatitis detection have been adapted for broader infectious disease surveillance, exemplifying cross-application of technologies. By working with multidisciplinary teams across genomics, immunology, and epidemiology, Dr. Ma has built comprehensive systems for Hepatitis outbreak response. He often emphasizes the interconnectedness of Hepatitis with social and economic determinants, advocating for equitable access to Hepatitis screening and treatment. His research has led to the implementation of molecular panels that detect multiple pathogens—including Hepatitis viruses—in a single assay. Through these efforts, he’s helped reduce the burden of Hepatitis-related liver disease in several regions. Dr. Ma’s holistic approach ensures that Hepatitis remains not only a research priority but also a cornerstone of modern infectious disease control strategies.

ACHIEVEMENTS AND ACCOLADES 🏅

Dr. Jinmin Ma’s contributions to Hepatitis research have earned him widespread recognition. He was honored as a Reserve Talent of High-Level Professional in Shenzhen, a testament to his pioneering work in Hepatitis virus surveillance and vaccine innovation. Numerous grants from the Shenzhen Science and Technology Commission and China’s Ministry of Science and Technology supported his Hepatitis-related breakthroughs. His publication record, boasting over 13,000 citations and an H-index of 14, highlights the global resonance of his Hepatitis-focused studies. As a reviewer for esteemed journals like The Lancet Respiratory Medicine and EClinicalMedicine, he evaluates cutting-edge research, often emphasizing Hepatitis virology. Dr. Ma’s editorial leadership for Frontiers in Cellular and Infection Microbiology has shaped special issues that highlight Hepatitis and co-infection dynamics. His accolades reflect a career devoted to translating Hepatitis science into life-saving technologies. He has also patented Hepatitis-related diagnostic systems, including methods for metagenomic classification and host immune profiling. These accolades not only honor individual achievement but also highlight the broader significance of Hepatitis research in the 21st century. As recognition of his work grows, so does the potential for Hepatitis control on a global scale. Through awards and impact, Dr. Ma keeps the fight against Hepatitis in sharp scientific and societal focus.

GLOBAL COLLABORATIONS AND KNOWLEDGE SHARING 🤝

Dr. Jinmin Ma’s Hepatitis research transcends borders, fostering a global network of scientific exchange. His collaborative projects with institutions in Europe, Southeast Asia, and Africa center around molecular epidemiology of Hepatitis viruses. These partnerships aim to standardize Hepatitis surveillance, especially in regions with high prevalence and limited diagnostic capacity. By organizing and contributing to international workshops, Dr. Ma disseminates the latest innovations in Hepatitis sequencing, resistance tracking, and vaccine design. His work with the University of Copenhagen and global virology consortia facilitates comparative analysis of Hepatitis strains across populations. He has also trained numerous junior researchers in techniques crucial to Hepatitis monitoring, such as mRNA quantification, droplet digital PCR, and metagenomics. This knowledge transfer accelerates Hepatitis eradication goals in resource-challenged areas. Dr. Ma ensures that Hepatitis research remains inclusive and collaborative, uniting virologists, clinicians, and data scientists under a shared mission. His joint publications on Hepatitis genotype shifts, co-infection with tuberculosis, and antiviral responses emphasize shared responsibility in public health. These efforts exemplify his belief that Hepatitis is a global issue requiring united scientific effort. Through cross-border collaboration, Dr. Ma elevates the standard and reach of Hepatitis research, ensuring knowledge translates into action worldwide.

LEGACY IN MOLECULAR VIROLOGY 🧪

Dr. Jinmin Ma’s legacy is firmly etched in the field of molecular virology, with Hepatitis at its center. He redefined approaches to studying Hepatitis virus structure, replication, and immune interaction by integrating bioinformatics and next-generation sequencing. His insights into Hepatitis B virus genome dynamics, including genotype switching and intra-host variability, are widely cited and referenced. His research showed how specific mutations in the Hepatitis B X gene could influence vertical transmission risks, a revelation that reshaped pediatric hepatology. Dr. Ma developed multi-pathogen diagnostic platforms that include sensitive detection for Hepatitis strains, making viral diagnostics more comprehensive. He also contributed to the early adoption of mRNA vaccine platforms tailored to Hepatitis control, influencing current vaccine strategies. His advocacy for real-time Hepatitis data analytics has improved outbreak forecasting models. Beyond bench science, his mentorship of early-career scientists has cultivated a new generation of Hepatitis researchers. Many of his trainees now lead their own Hepatitis-focused labs. Dr. Ma’s legacy isn’t confined to publications or patents—it lives in institutional frameworks and global dialogues on Hepatitis control. Through decades of persistent innovation, his molecular virology legacy cements Hepatitis as both a scientific challenge and a public health priority.

FUTURE VISIONS FOR HEPATITIS CONTROL 🚀

Looking ahead, Dr. Jinmin Ma envisions a world where Hepatitis is no longer a global health threat. He continues to push scientific boundaries by advancing ultra-rapid diagnostic tools that can detect emerging Hepatitis variants within hours. His current research explores personalized Hepatitis vaccines using real-time transcriptomic data to tailor immune responses. He is also piloting artificial intelligence models that predict Hepatitis treatment outcomes based on genetic and epigenetic signatures. These next-gen tools could revolutionize how we manage Hepatitis in both endemic and non-endemic regions. Dr. Ma advocates for stronger integration of Hepatitis diagnostics into routine healthcare systems, especially in underserved areas. He’s also proposing cloud-based surveillance platforms to share Hepatitis data across national borders in real time. As climate change alters viral transmission patterns, Dr. Ma is studying how environmental shifts impact Hepatitis epidemiology. Through strategic collaborations, he hopes to bring affordable and scalable Hepatitis interventions to communities worldwide. His future plans include establishing a dedicated Hepatitis Innovation Hub within BGI to consolidate research, training, and implementation efforts. Dr. Ma’s forward-looking approach ensures that Hepatitis remains a solvable challenge through science, collaboration, and dedication. His vision inspires a new era in Hepatitis prevention, treatment, and global elimination efforts.

NOTABLE PUBLICATION

  • Title: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
    Authors: R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, ...
    Journal: The Lancet, Vol. 395 (10224), pages 565–574, 2020

  • Title: Selection of reference genes for quantitative real-time PCR in bamboo (Phyllostachys edulis)
    Authors: C. Fan, J. Ma, Q. Guo, X. Li, H. Wang, M. Lu
    Journal: PLOS ONE, Vol. 8 (2), e56573, 2013

  • Title: Dominant subtype switch in avian influenza viruses during 2016–2019 in China
    Authors: Y. Bi, J. Li, S. Li, G. Fu, T. Jin, C. Zhang, Y. Yang, Z. Ma, W. Tian, J. Li, S. Xiao, ...
    Journal: Nature Communications, Vol. 11 (1), Article 5909, 2020

  • Title: Altered respiratory virome and serum cytokine profile associated with recurrent respiratory tract infections in children
    Authors: Y. Li, X. Fu, J. Ma, J. Zhang, Y. Hu, W. Dong, Z. Wan, Q. Li, Y.Q. Kuang, K. Lan, ...
    Journal: Nature Communications, Vol. 10 (1), Article 2288, 2019

  • Title: Sequence recombination and conservation of Varroa destructor virus-1 and deformed wing virus in field collected honey bees (Apis mellifera)
    Authors: H. Wang, J. Xie, T.G. Shreeve, J. Ma, D.W. Pallett, L.A. King, R.D. Possee
    Journal: PLOS ONE, Vol. 8 (9), e74508, 2013

Dayu Liu – Diagnosis of Infectious Diseases – Best Researcher Award

Posted on by Infectious

Dayu Liu - Diagnosis of Infectious Diseases - Best Researcher Award

the Second Affiliated Hospital, School of Medicine, South China University of Technology - China

AUTHOR PROFILE

SCOPUS

EARLY ROOTS IN MEDICAL SCIENCE 🧬

Dr. Dayu Liu's foundational journey into the world of science began with a Bachelor of Science in Clinical Medicine from Dalian Medical University, where he cultivated a strong interest in pathology and diagnostics. He further refined his expertise through a Master’s in Pathology at the same university, driven by his passion for biomedical research. Motivated to explore the frontiers of analytical innovation, Dr. Liu pursued a Ph.D. in Analytical Chemistry at the University of Chinese Academy of Sciences (UCAS), where his thesis focused on microfluidic chip research. This advanced study marked the inception of his specialization in micro-analytical systems, a field directly contributing to the advancement of the Diagnosis of Infectious Diseases. Through these early academic pursuits, Dr. Liu not only gained technical mastery but also a comprehensive understanding of how microfluidic systems could be applied to rapidly detect and monitor pathogens. These experiences laid the scientific and clinical groundwork that now defines his work. Today, his early education continues to inform his cutting-edge innovations in laboratory medicine, exemplifying how fundamental medical training can evolve into pioneering research impacting the Diagnosis of Infectious Diseases globally.

MICROFLUIDIC BREAKTHROUGHS IN DIAGNOSTICS 🔬

Dr. Liu’s groundbreaking work in microfluidic chip technology stands at the intersection of engineering and medicine, revolutionizing the Diagnosis of Infectious Diseases. As Director of the Microfluidic In Vitro Diagnostics Laboratory at the Second Affiliated Hospital of South China University of Technology, he leads transformative research in developing portable, rapid, and precise diagnostic platforms. His postdoctoral tenure at the Hong Kong University of Science and Technology provided him with essential experience in micro-analytical systems, which he has since applied to real-world healthcare challenges. By engineering chips capable of analyzing minute biological samples, Dr. Liu has enabled quicker and more cost-effective diagnostics, especially vital for early-stage detection of infectious diseases. His work in this domain includes the creation of high-content diagnostic systems that can process large volumes of patient data, thereby improving the accuracy and speed of infectious disease detection. These advancements are essential for responding to disease outbreaks and managing global health emergencies. His technology also supports personalized medicine, ensuring that patients receive treatments tailored to their biological profiles. Through microfluidics, Dr. Liu is not only enhancing laboratory workflows but also redefining the operational standards for the Diagnosis of Infectious Diseases in both clinical and remote settings.

PIONEERING RESEARCH AND GLOBAL IMPACT 🌍

Dr. Dayu Liu has emerged as a leading voice in the global scientific community through his contributions to diagnostic research. His work has significant implications for public health, particularly in the Diagnosis of Infectious Diseases, where accurate and timely detection can mean the difference between containment and catastrophe. As a principal investigator for five National Natural Science Foundation of China (NSFC) General Program Grants and over ten provincial and municipal research projects, Dr. Liu has secured consistent support for his groundbreaking research. His studies bridge the gap between laboratory innovation and clinical application, especially in under-resourced healthcare systems. His focus on developing microfluidic chip-based diagnostics has enabled large-scale screening and epidemiological surveillance, bolstering global preparedness for infectious disease threats. Through collaborations with international journals and institutions, he disseminates knowledge that transcends borders. His scholarly contributions, with over 50 peer-reviewed articles, have introduced novel methodologies now employed by diagnostics labs around the world. In championing scientific transparency and reproducibility, Dr. Liu's research continues to inform policy and practice related to the Diagnosis of Infectious Diseases, illustrating the role of academic innovation in safeguarding human health on a global scale.

TECHNOLOGICAL INNOVATION IN LABORATORY MEDICINE ⚙️

Technological ingenuity is at the heart of Dr. Liu's contributions to laboratory medicine, particularly concerning the Diagnosis of Infectious Diseases. By designing and engineering microfluidic platforms, he has pushed the boundaries of what’s possible in diagnostic technology. His innovations offer compact, easy-to-use, and highly accurate tools that are reshaping how infectious agents are identified and quantified. As a researcher at the Second Affiliated Hospital of South China University of Technology, he continually translates engineering principles into medical breakthroughs. His laboratory focuses on producing integrated systems capable of simultaneously analyzing multiple biomarkers—crucial for differentiating between viral and bacterial infections quickly. With more than 20 patents to his name, Dr. Liu's inventions extend beyond academia, providing commercial and clinical avenues for next-generation diagnostics. These systems have already shown effectiveness in detecting diseases like COVID-19, dengue, and tuberculosis, aligning with global efforts to strengthen disease surveillance. Through innovation in biosensors, signal amplification, and sample handling, his lab sets new standards in point-of-care diagnostics. As infectious diseases remain a persistent threat, Dr. Liu’s technology ensures that the Diagnosis of Infectious Diseases becomes more responsive, affordable, and accessible, fulfilling urgent global health needs.

MENTORSHIP AND ACADEMIC LEADERSHIP 🎓

Beyond the laboratory bench, Dr. Liu plays a vital role in shaping future scientific leaders. As an advisor for both Master's and Ph.D. students at South China University of Technology, he actively mentors the next generation of researchers, many of whom are now working on projects directly related to the Diagnosis of Infectious Diseases. His mentorship philosophy emphasizes rigorous methodology, interdisciplinary collaboration, and ethical responsibility. Under his guidance, students are trained in advanced diagnostic technologies, including microfluidics, bioinformatics, and molecular biology. Dr. Liu encourages his mentees to bridge research and real-world application, ensuring their work remains clinically relevant. He has cultivated a thriving academic environment where curiosity and innovation are prioritized. His influence as a mentor extends through co-authored publications, joint patent applications, and international conference presentations. Many of his students have gone on to secure academic and industry positions, contributing to global efforts in disease detection and management. Dr. Liu’s dedication to education not only amplifies his impact but also ensures that the field of Diagnosis of Infectious Diseases continues to evolve, benefiting from the fresh perspectives and skills of well-trained young scientists.

SCIENTIFIC ACHIEVEMENTS AND RECOGNITION 🏅

Dr. Dayu Liu’s prolific scientific output and numerous accolades reflect his standing in the international research community. With over 50 peer-reviewed articles in renowned journals such as Advanced Science, Lab on a Chip, and Analytical Chemistry, his work has consistently advanced the field of Diagnosis of Infectious Diseases. His research is widely cited and has influenced diagnostic protocols and policy formulations. Dr. Liu’s intellectual property portfolio includes more than 20 patents, many of which have practical applications in commercial diagnostic kits. These contributions have earned him regional and national recognition, solidifying his reputation as a leading innovator in diagnostic medicine. He is frequently invited to speak at global conferences and serve on editorial boards, further underscoring the international value of his research. Awards from scientific societies and funding bodies have validated the impact of his work on both clinical practice and public health. Dr. Liu’s achievements illustrate a career committed to solving real-world problems through scientific inquiry. His advancements continue to inspire other researchers and contribute to a more precise, rapid, and scalable approach to the Diagnosis of Infectious Diseases, thereby enhancing disease control and patient care globally.

VISION FOR THE FUTURE OF DIAGNOSTICS 🔮

Looking forward, Dr. Liu envisions a diagnostic landscape where rapid, decentralized, and personalized testing becomes the norm, especially in the realm of the Diagnosis of Infectious Diseases. His future work aims to integrate artificial intelligence and machine learning into microfluidic systems to enable predictive diagnostics. By harnessing big data and cloud-based platforms, he aspires to create real-time monitoring tools that can anticipate outbreaks before they spread. His lab is currently exploring novel biosensors capable of detecting emerging pathogens with unprecedented sensitivity. Dr. Liu also plans to expand collaborations with international institutions to promote technology transfer and equitable access to diagnostics in low-resource settings. His commitment to sustainable and scalable solutions will be critical in tackling future pandemics and antimicrobial resistance. Through continuous innovation and interdisciplinary synergy, Dr. Liu is determined to make diagnostics more inclusive, accurate, and efficient. As he charts the path forward, his work remains grounded in one central mission: advancing the Diagnosis of Infectious Diseases to protect global health. His legacy will not only be measured in patents or publications but in lives saved and healthcare systems strengthened through intelligent, accessible diagnostic science.

NOTABLE PUBLICATION

  • Title: Pheno-Molecular Testing Enabled by Multiplex Droplet Digital PCR for Rapid and High-Content Detection of Carbapenem-Resistant Enterobacterales
    Journal: Analytical Chemistry
    Authors: (Author names not specified in the input — please provide or clarify if needed)

  • Title: Droplet Pairing-Merging Enabled Digital RPA-CRISPR/Cas12a (DIMERIC) Assay for Rapid and Precise Quantification of Hepatitis B Virus DNA
    Journal: Biosensors and Bioelectronics
    Authors: (Author names not specified in the input)

  • Title: Automated Droplet Ejection from a Digital Microfluidics Sample Pretreatment Device Enables Batch-Mode Chemiluminescence Immunoassay
    Journal: Analytical Chemistry
    Authors: (Author names not specified in the input)

  • Title: Forming Single-Cell-Derived Colon Cancer Organoid Arrays on a Microfluidic Chip for High Throughput Tumor Heterogeneity Analysis
    Journal: ACS Biomaterials Science and Engineering
    Authors: (Author names not specified in the input)

  • Title: Selective Expansion of Renal Cancer Stem Cells Using Microfluidic Single-Cell Culture Arrays for Anticancer Drug Testing
    Journal: Lab on a Chip
    Authors: (Author names not specified in the input)

Theodora Mahoukede Zohoncon – Hepatitis – Best Researcher Award

Posted on by Infectious

Theodora Mahoukede Zohoncon - Hepatitis - Best Researcher Award

Université Saint Thomas d'Aquin - Burkina Faso

AUTHOR PROFILE

ORCID

ACADEMIC ROOTS AND RISING 🌱

Prof. ZOHONCON Theodora M.’s academic journey began with a robust foundation in pharmacy, laying the groundwork for a future in scientific leadership. She earned her Doctorate in Pharmacy (PharmD) and later specialized in medical biology with a strong research orientation. Her early educational achievements were not merely academic milestones but stepping stones into deeper biomedical inquiries, particularly infectious diseases such as Hepatitis. This early exposure inspired her to pursue advanced research degrees, culminating in a PhD in Applied Microbiology and Immunology. Her initial focus on microbial pathogenesis and clinical diagnostics paved the way for her career-long engagement with virology. With a growing interest in Hepatitis research, she developed laboratory skills and theoretical insight that would eventually translate into impactful public health applications. Her academic rigor was matched by a passion for mentorship, demonstrated by her commitment to training students and supervising theses in related biomedical disciplines. Her foundational years reveal a scholar devoted to science and service, where Hepatitis studies began to form the nucleus of a broader agenda addressing viral infections in Africa. From her earliest lectures to her laboratory milestones, Prof. ZOHONCON’s academic roots illustrate a steady ascent anchored in excellence, with Hepatitis always central to her evolving research identity.

PROFESSIONAL MILESTONES & LEADERSHIP 🏛️

Prof. ZOHONCON has risen to become a key figure in biomedical sciences and health administration. As a university professor and director of multiple laboratories, she has consistently blended academic insight with institutional leadership. Her tenure at Joseph Ki-Zerbo University is marked by dedicated teaching and pivotal administrative roles, including positions on ethics committees and curriculum development boards. A significant portion of her professional path has been devoted to the development of diagnostic protocols for viral diseases, particularly Hepatitis. She has overseen critical infrastructure that supports molecular biology, immunology, and microbiological research while also leading public health-focused initiatives. Her work with national and regional networks further exemplifies her commitment to applied science that benefits community health. As a respected voice in virological surveillance and biosafety, Prof. ZOHONCON regularly collaborates with health ministries and international bodies to combat Hepatitis outbreaks. These collaborations bridge the gap between academic research and real-world medical needs. Her leadership positions are not only testaments to her administrative capacity but reflect her advocacy for prioritizing Hepatitis control and research in national health strategies. In every professional milestone, her emphasis on Hepatitis as a public health priority has remained constant and resolute.

SCIENTIFIC CONTRIBUTIONS IN HEPATITIS RESEARCH 🔬

Prof. ZOHONCON’s scientific portfolio is rich with impactful research in virology, with a particular emphasis on Hepatitis viruses. Her contributions span the development of diagnostic tools, laboratory biosafety protocols, and epidemiological surveillance techniques. One of her most significant scientific endeavors includes studies on the molecular epidemiology of Hepatitis B and C, helping to elucidate transmission pathways and genotypic variations in Burkina Faso and the West African region. Through her publications and collaborative projects, she has contributed to a better understanding of viral hepatitis prevalence, risk factors, and resistance patterns. She played a leading role in projects funded by international organizations focused on improving the early detection and treatment outcomes of Hepatitis infections. Her research is guided by a vision to make diagnostics accessible and reliable in low-resource settings. Beyond lab-based work, she’s involved in translating research into health policy, aiming to improve national response strategies against Hepatitis. Her ability to navigate both the academic and applied realms has positioned her as a regional authority on Hepatitis virology. Through dozens of scientific articles, conference presentations, and field surveys, Prof. ZOHONCON has continually advanced the frontiers of knowledge in Hepatitis research, directly influencing public health protocols and disease control efforts.

GLOBAL COLLABORATIONS AND NETWORKS 🌍

International collaboration has been a cornerstone of Prof. ZOHONCON’s strategy in elevating Hepatitis research. Her partnerships with institutions across Africa, Europe, and international health agencies have catalyzed critical research into viral epidemiology and immunopathology. She has participated in WHO-sponsored programs and has led collaborative studies with institutions such as the Institut Pasteur and the West African Health Organization (WAHO), focusing on capacity building and laboratory diagnostics for Hepatitis and other viral infections. These global engagements not only advanced her own research but also enhanced regional preparedness through training programs, inter-laboratory benchmarking, and the development of diagnostic guidelines. Prof. ZOHONCON has emphasized the need for a cross-border approach to tackle Hepatitis, considering the migratory nature of populations and the variable access to healthcare infrastructure. Her ability to synthesize international standards with local realities has made her a valuable liaison between Burkina Faso’s health system and global research agendas. These alliances have yielded joint publications, regional policy briefs, and enhanced research funding channels. By fostering an international research ecosystem, Prof. ZOHONCON ensures that Hepatitis remains on the global health agenda, with African data and perspectives significantly shaping future directions.

TEACHING AND MENTORSHIP LEGACY 👩‍🏫

Prof. ZOHONCON is deeply invested in the academic and professional development of future scientists. Her lectures in immunology, virology, and molecular diagnostics have shaped hundreds of students, many of whom now contribute to the medical sciences and public health. As a supervisor and mentor for undergraduate, master's, and doctoral candidates, she has consistently emphasized the importance of research in diseases like Hepatitis. Her mentorship goes beyond technical knowledge—she instills in her mentees a sense of responsibility toward addressing the health challenges of the region. Several of her supervised theses and student projects have directly contributed to understanding Hepatitis epidemiology, prevention, and diagnosis. She also organizes hands-on laboratory training and workshops, often in collaboration with regional networks, to ensure that students gain both theoretical and practical competencies. Prof. ZOHONCON's teaching philosophy integrates research with application, particularly in the context of Hepatitis, ensuring that learners understand both the science and the social impact of their work. Her mentorship legacy is reflected in a growing community of African researchers and healthcare professionals equipped to confront viral infections, with Hepatitis remaining a central theme in their academic journeys and professional endeavors.

AWARDS, HONORS, AND RECOGNITION 🏅

Prof. ZOHONCON’s distinguished contributions have earned her numerous accolades, solidifying her as a prominent voice in biomedical sciences. Recognized both nationally and internationally, she has received awards for excellence in teaching, groundbreaking research, and public health leadership. Her work on Hepatitis diagnostics and epidemiology has been particularly praised, receiving commendations from academic societies and health agencies alike. One of her most prestigious honors includes recognition from the Ministry of Health for her advisory role in Hepatitis control programs and her impact on laboratory capacity strengthening. She has been invited as a keynote speaker at major virology and infectious disease conferences, where her insights on Hepatitis surveillance and public health policies are highly sought. These recognitions are not only personal achievements but also reinforce the visibility and urgency of Hepatitis research in global and regional scientific discourse. Through every award, Prof. ZOHONCON reaffirms her dedication to leveraging science for societal benefit. Her accolades reflect a career not just of excellence, but of enduring impact—especially in the fight against Hepatitis and its associated health burdens.

FUTURE VISION AND LASTING IMPACT 🌟

Looking ahead, Prof. ZOHONCON envisions a future where Hepatitis is no longer a silent epidemic in Africa. Her ongoing projects focus on strengthening early detection frameworks, expanding molecular diagnostic capabilities, and promoting vaccination coverage—especially in underserved communities. She is actively pursuing research that intersects genomics and public health to better predict Hepatitis outbreaks and resistance patterns. Her long-term goal is to establish a center of excellence in West Africa dedicated to virology and infectious diseases, with Hepatitis research as a flagship focus. Beyond scientific aims, she advocates for policy reform and education campaigns to demystify Hepatitis and reduce stigma. Her impact will continue through her mentees, institutional initiatives, and international collaborations. Prof. ZOHONCON’s legacy is rooted in her unwavering dedication to science as a tool for transformation. As she continues to lead from the lab, the lecture hall, and the policy table, she exemplifies how a singular focus—such as Hepatitis—can become the nucleus of widespread change. Her future contributions promise to leave an indelible mark on both the scientific community and the public health landscape of Africa and beyond.

NOTABLE PUBLICATION

  • Title: Involvement of ERCC1 (rs3212986) and ERCC2 (rs1799793, rs13181) polymorphisms of DNA repair genes in breast cancer occurrence in Burkina Faso
    Authors: Adico MDW, Zouré AA, Sombié HK, Kiendrebeogo TI, Dabré S, Amegnona LJ, Bakyono BS, Traoré L, Ouedraogo TC, Ouedraogo RA, et al.
    Journal: Molecular Genetics & Genomic Medicine
  • Title: Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso
    Authors: Traoré ADD, Ky BD, Traoré L, Zohoncon TM, Zouré AA, Yonli AT, Sombié HK, Sorgho PA, Elvira Bazié BVJT, Tovo SFA, et al.
    Journal: Prostate Cancer
  • Title: KIR2DL2, KIR2DL5A and KIR2DL5B Genes Induce Susceptibility to Dengue Virus Infection, while KIR3DL3 and KIR2DS5 Confer Protection
    Authors: Tapsoba ASA, Djigma FW, Bayala B, Sorgho PA, Traore L, Zohoncon TM, Bello SOT, Bado P, Bazie BVEJT, Yougbare F, et al.
    Journal: Mediterranean Journal of Hematology and Infectious Diseases
  • Title: First detection of mutated ERG11 gene in vulvovaginal Candida albicans isolates at Ouagadougou/Burkina Faso
    Authors: Dovo EE, Zohoncon TM, Tovo SF, Soubeiga ST, Kiendrebeogo IT, Yonli AT, Ouedraogo RA, Dabire AM, Djigma FW, Nadembega CW, et al.
    Journal: BMC Infectious Diseases
  • Title: Molecular Epidemiology of Human Herpes Virus Type 8 Among Patients with Compromised Immune System in Ouagadougou, Burkina Faso
    Authors: Biatougou NM, Ouedraogo MS, Soubeiga ST, Zohoncon TM, Ouedraogo P, Obiri-Yeboah D, Tapsoba ASA, Kiendrebeogo TI, Sagna T, Niamba P, et al.
    Journal: HIV/AIDS (Auckland, N.Z.)

Anara Babayeva – Antibiotics – Best Researcher Award

Posted on by Infectious

Anara Babayeva - Antibiotics - Best Researcher Award

Mugla Sıtkı Kocman University - Turkey

AUTHOR PROFILE 

GOOGLE SCHOLAR

EARLY ACADEMIC ROOTS 🌱

Anara Babayeva, born in Baku, Azerbaijan, on February 9, 1993, embarked on her academic journey with a passion for biology that would soon shape a compelling scientific career. After completing high school at A.S. Xalilov No. 263, she earned her bachelor's degree in biology from Azerbaijan State Pedagogical University. Her academic curiosity led her to Turkey, where she pursued and completed her master’s degree in biology at Muğla Sıtkı Koçman University. It was during this period that Anara began cultivating her deep scientific interest in molecular biology, microbiology, and the emerging field of functional genomics. The foundation she built during these formative years prepared her to engage in highly complex studies involving transcriptomics, metabolomics, and proteomics—fields crucial in the global fight against resistant bacteria. Even as a student, she was drawn to innovative research areas, especially the use of natural compounds and novel molecules like boron-derived antibiotics. Her early education served as a launchpad for numerous national and international research projects focused on bacterial gene expression, antimicrobial resistance, and metabolic profiling. Her work consistently demonstrated both a profound understanding of biological systems and a visionary approach toward leveraging antibiotics for therapeutic and diagnostic breakthroughs.

ADVANCED SCIENTIFIC EXPLORATIONS 🔬

At the graduate and post-graduate levels, Anara Babayeva immersed herself in the intricacies of biotechnology and molecular research. Her focus sharpened on developing novel methodologies to understand how antibiotics, particularly boron-containing compounds like epetraborole, interact with pathogenic strains such as Escherichia coli. At Muğla Sıtkı Koçman University, she became an active researcher in various TÜBİTAK and BAP-funded projects, contributing significantly to studies investigating bacterial gene responses, antimicrobial resistance, and phenolic compounds. Anara's efforts included advanced proteomic and transcriptomic analyses, often utilizing nano LC-MS/MS, 2D gel electrophoresis, and microarray platforms. Her expertise expanded through work on functional genomics, including KEIO mutant screening and ASKA clone analysis, highlighting her unique ability to decode complex genetic systems. Through these cutting-edge methods, Anara explored the biochemical and genomic impact of antibiotics on cellular networks. This phase of her career showcased not just technical proficiency but also a bold drive to innovate in diagnostics and treatment methodologies. Her work during this period not only contributed to scientific literature but also provided a deeper understanding of how natural compounds and synthetic antibiotics could serve as the cornerstone of next-generation antimicrobial strategies.

GROUNDBREAKING RESEARCH IN ANTIBIOTICS 🧪

Anara Babayeva’s scientific pursuits have consistently centered around the dynamic and urgent field of antibiotics research. Her hallmark contributions involve the investigation of epetraborole, a boron-containing experimental drug, and its mechanisms against bacterial strains. She has taken a leading role in several TÜBİTAK-funded projects examining how specific genes and proteins in Escherichia coli respond to antimicrobial stress, using technologies like NMR metabolomics and proteomics to detect subtle molecular changes. In particular, her research revealed novel gene targets and metabolic pathways affected by boron-based antibiotics, advancing our understanding of bacterial resistance and tolerance mechanisms. Through transcriptomic profiling, she has mapped how gene overexpression or deletion can modify bacterial behavior under drug pressure. These insights are essential in combating multidrug-resistant organisms, which pose a growing threat to global health. Anara’s ability to synthesize bioinformatics data with wet-lab experimentation has propelled her work to the forefront of functional antibiotic discovery. Her pioneering studies underscore how interdisciplinary approaches can unlock powerful antimicrobial solutions, turning theoretical findings into practical applications. By bridging molecular biology and clinical microbiology, she continues to redefine how antibiotics are conceptualized and tested in modern laboratories.

NATURAL COMPOUNDS AND ANTIMICROBIAL INNOVATION 🌿

In addition to synthetic antibiotics, Anara Babayeva has conducted extensive research on natural compounds with antimicrobial properties. Her investigations into Turkish propolis, phenolic acids, and even sea urchin extracts highlight her interest in exploring bioactive molecules from diverse ecosystems. She played key roles in studies examining the antimicrobial and anticancer effects of substances like Dracunculus vulgaris, Rosularia serrata, Amanita virosa, and Trichaptum biforme. These experiments often employed metabolomic profiling and transcriptomic studies to determine how natural extracts affect microbial survival, with findings suggesting that nature-derived compounds could complement traditional antibiotics or even pave the way for new drug classes. By examining how compounds such as propolis influence nucleic acid metabolism and protein expression in E. coli, Anara has contributed important data to the field of natural product pharmacology. Her research also sheds light on how bacteria develop resistance or tolerance to both synthetic and natural antimicrobial agents. This dual approach—studying both commercial antibiotics and bioactive compounds—illustrates her comprehensive understanding of microbial defense strategies and her commitment to uncovering sustainable, multifaceted antimicrobial therapies.

ACCOLADES AND ACADEMIC CONTRIBUTIONS 🏆

Throughout her career, Anara Babayeva has earned widespread recognition for her contributions to molecular biology and antibiotics research. Her scholarly work has been featured in respected journals such as Frontiers in Life Sciences and Related Technologies, Journal of Applied Microbiology, and International Journal of Peptide Research and Therapeutics. She has authored and co-authored impactful studies on epetraborole, bacterial gene responses, and antimicrobial resistance. Moreover, Anara has presented her findings at prominent international conferences, where her work on boron-based antibiotics, gene expression, and metabolomics has drawn praise from the academic community. Her participation in events such as the International Proteomics Congress and multiple TÜBİTAK conferences demonstrates her active engagement in scientific dialogue. Her reputation as an innovative and meticulous researcher has made her a respected figure in the antibiotic discovery field. Notably, her efforts are not limited to publication—she has been actively involved in mentoring, conducting experimental designs, and guiding younger researchers in the lab. These contributions ensure that her knowledge and passion for antibiotics continue to influence future scientific exploration and public health advancements.

SCIENTIFIC IMPACT AND GLOBAL REACH 🌍

Anara Babayeva’s research has transcended national boundaries, contributing valuable insights to the global scientific community’s understanding of antibiotics. Her interdisciplinary methodology—integrating genomics, proteomics, and metabolomics—has made significant strides in elucidating how bacteria interact with both synthetic and natural antimicrobial agents. By targeting genes associated with resistance and metabolic adaptation, she has helped pinpoint vulnerable molecular pathways, offering promising new targets for therapeutic development. Anara’s findings not only contribute to scientific journals but also inform broader discussions on antibiotic stewardship and resistance management worldwide. Her work is increasingly relevant in the age of rising antibiotic-resistant infections, especially as health organizations emphasize the need for next-generation antimicrobial drugs. Collaborations with international partners and participation in bilateral research projects further highlight her influence beyond Turkey and Azerbaijan. Her data on propolis and boron-derived antibiotics have implications for pharmaceutical development, bioengineering, and public health strategies. Anara’s science-driven advocacy promotes rational drug design and emphasizes a balance between innovation and sustainability in the use of antibiotics, making her a crucial voice in the global effort to protect the efficacy of life-saving antimicrobial therapies.

VISION FOR THE FUTURE OF ANTIBIOTICS RESEARCH 🔭

Looking ahead, Anara Babayeva envisions a future where advanced technologies converge to develop smarter, safer, and more sustainable antibiotics. Her ongoing research focuses on identifying novel gene-drug interactions, using tools like CRISPR screening, AI-driven bioinformatics, and NMR-based metabolomics. With a strong foundation in functional genomics and microbial systems biology, she aims to build integrated models that predict bacterial responses to emerging drug candidates. She is particularly interested in the synergy between synthetic molecules and natural extracts, which could minimize resistance development while enhancing drug efficacy. Future projects include studying microbial ecology under antimicrobial stress and developing biosensors for antibiotic susceptibility testing. Anara is also committed to mentoring a new generation of scientists who can carry forward the fight against antibiotic resistance. As antibiotics become an increasingly precious resource, her research will help redefine how they are developed, prescribed, and preserved. Her legacy is poised to be one of scientific rigor and visionary leadership—pioneering not just new compounds but also a paradigm shift in how the world understands and utilizes antibiotics for both human and environmental health.

NOTABLE PUBLICATION

  • Title: NMR metabolomics analysis of Escherichia coli cells treated with Turkish propolis water extract reveals nucleic acid metabolism as the major target
    Authors: ES Elgin, ŞS Çatav, A Babayeva, H Kim, E Dibek, B Çöl, YK Chae, ...
    Journal: Journal of Applied Microbiology

 

  • Title: Bor içeren bazı biyoaktif bileşikler
    Authors: E Dibek, A Babayeva, MS Kürkçü, NA Çöl, B Çöl
    Journal: Journal of Boron

 

  • Title: Genome-wide screen of Escherichia coli Keio mutant line identifies genes related to propolis effect
    Authors: E Dibek, A Babayeva, ES Elgin, MS Kürkçü, B Çöl
    Journal: European Food Research and Technology

 

  • Title: The Cytotoxic Effects of Turkish Bee Venom (Apis mellifera) on Selected Cancer Cell Lines
    Authors: A Babayeva, E Dibek, İ Kıvrak, B Çöl
    Journal: International Journal of Peptide Research and Therapeutics

 

  • Title: Genome-wide Screening of the Escherichia coli Keio Knockout Collection Identifies Genetic Determinants of Epetraborole Hypersusceptibility
    Authors: A Babayeva, B Çöl
    Journal: European Journal of Clinical Microbiology & Infectious Diseases

Edmund Ossai – Tuberculosis – Best Researcher Award

Posted on by Infectious

Edmund Ossai - Tuberculosis - Best Researcher Award

Ebonyi State University Abakaliki, Nigeria - Nigeria

AUTHOR PROFILE

GOOGLE SCHOLAR

EARLY ACADEMIC FOUNDATIONS 🎓 | TUBERCULOSIS PATHWAY BEGINS

Dr. Edmund Ndudi Ossai's journey into the realm of public health and Tuberculosis research began with a strong academic background rooted in medicine. His education at the College of Health Sciences, Ebonyi State University, Abakaliki, Nigeria, laid a foundational understanding of community medicine—an essential field in combating infectious diseases. Early in his career, he demonstrated a sharp interest in disease epidemiology, especially diseases with widespread public health impacts like Tuberculosis. These academic pursuits eventually led him to embrace research that integrates technology with community-based health strategies. Dr. Ossai’s capacity for interdisciplinary learning and his consistent focus on infectious diseases positioned him as a valuable contributor to Nigeria's health sector. Tuberculosis, with its deep societal and clinical implications, became a central concern in his research and professional outlook. His early exposure to the burden of TB in developing regions inspired him to investigate not just the biological aspects of the disease, but also the operational and systemic bottlenecks in diagnostic systems. This early academic period was marked by curiosity, innovation, and a desire to create sustainable public health solutions that would later shape his renowned work in Truenat-based TB diagnostics across Nigerian health facilities.

PROFESSIONAL ENDEAVORS ⚕️ | DRIVING TUBERCULOSIS DIAGNOSTICS

In his professional journey, Dr. Edmund Ndudi Ossai has emerged as a pivotal figure in Nigeria’s Tuberculosis control initiatives. As a faculty member in the Department of Community Medicine at Ebonyi State University, he has balanced academic roles with active field engagement. His most significant contribution came during his involvement with the pilot implementation of Truenat diagnostic platforms across 38 health facilities in Nigeria. Tuberculosis remains a leading health challenge in the country, and Dr. Ossai’s work targeted the systemic errors in existing diagnostic chains. The research he led focused on identifying factors responsible for unsuccessful tests and high error rates, revealing that while error rates were generally low, specific facility-level issues like cartridge errors and PCR internal control failures needed urgent intervention. Under his leadership, evidence-based strategies were proposed to enhance training curricula for laboratory personnel and improve operational efficiency. Through collaborative work with agencies like the Federal Ministry of Health, USAID, and the Stop TB Partnership, his professional trajectory has continuously intersected with global Tuberculosis eradication goals. Dr. Ossai’s career is a testament to applied public health work—where scientific inquiry is directly tied to the betterment of diagnostic infrastructure and TB patient outcomes.

RESEARCH FOCUS 🔬 | INNOVATIONS AGAINST TUBERCULOSIS

The cornerstone of Dr. Edmund Ndudi Ossai’s research lies in improving diagnostic efficiency for Tuberculosis in Nigeria. He spearheaded a groundbreaking retrospective cross-sectional study analyzing over 56,000 Truenat DNA extractions and MTB test results. This meticulous work provided actionable insights into the error rates of Truenat diagnostic platforms, which were relatively low—1.8% for Trueprep DNA extraction and 2.4% for Truenat MTB tests. His research did not stop at mere statistics; it delved into the root causes of high error rates such as cartridge malfunction and internal control failures in PCR procedures. Tuberculosis control heavily depends on accurate and timely diagnosis, and Dr. Ossai’s work bridged a crucial knowledge gap in operational diagnostics. Importantly, his research confirmed that no specific socio-demographic factor significantly influenced the error outcomes, suggesting that systemic training and technological interventions would yield better diagnostic consistency. His dedication to improving point-of-care TB diagnostics reflects a forward-thinking research agenda. By focusing on real-world implementation, Dr. Ossai champions the evolution of diagnostic technologies like Truenat as scalable, reliable tools against Tuberculosis in both urban and rural health settings.

COLLABORATIVE CONTRIBUTIONS 🤝 | TEAMING UP FOR TUBERCULOSIS

Tuberculosis control is a multidisciplinary challenge, and Dr. Edmund Ndudi Ossai has consistently worked within collaborative frameworks to ensure robust, real-world impact. His Truenat project involved experts from the Federal Ministry of Health, USAID Nigeria, KNCV Nigeria, the Stop TB Partnership in Geneva, and international consultants. The team, composed of public health officials, data analysts, and diagnostic specialists, operated across 38 Truenat sites in Nigeria. This cross-functional synergy was pivotal in uncovering diagnostic inefficiencies and optimizing the TB testing ecosystem. Dr. Ossai’s ability to coordinate among various stakeholders helped harmonize the technical objectives with national health priorities. Tuberculosis remains a complex epidemic demanding synchronized intervention, and his collaborative model served as a blueprint for successful scale-up strategies. He also emphasized capacity building by proposing improvements in the Truenat training curriculum—ensuring that laboratory personnel are better equipped to manage error codes and machine anomalies. His collaborative ethos not only enhanced data quality and study execution but also cultivated a spirit of shared ownership, which is crucial for sustainable Tuberculosis program outcomes. These partnerships significantly magnified the study’s implications and laid the groundwork for policy reform in diagnostic practices across Nigeria.

IMPACT AND INFLUENCE 🌍 | SHAPING TUBERCULOSIS STRATEGIES

Dr. Edmund Ndudi Ossai’s research has had a lasting impact on Nigeria’s Tuberculosis control policies. His findings from the Truenat pilot study have reshaped how diagnostic errors are interpreted and addressed at the health facility level. By identifying the frequency and distribution of errors, his work has provided a practical framework for the Federal Ministry of Health to enhance TB diagnostic protocols. Tuberculosis diagnosis in resource-limited settings often suffers from a lack of precision and operational feedback loops. Dr. Ossai’s influence has shifted this narrative toward data-driven interventions. Health facilities that once struggled with unclear error sources now benefit from standardized processes informed by his research. His call for revising the national Truenat training curriculum has already sparked conversations among policymakers, potentially improving laboratory performance on a large scale. Beyond institutional settings, his research has influenced public health discourse on integrating technology into infectious disease control. By emphasizing low error rates and practical improvements, Dr. Ossai’s work reassures stakeholders of Truenat’s potential in scaling TB detection. The ripple effects of his contributions are seen in better diagnostics, timely treatment, and a reinvigorated approach to combating Tuberculosis in Nigeria.

ACCOLADES AND RECOGNITION 🏅 | TUBERCULOSIS CHAMPION

For his relentless contributions to Tuberculosis diagnostics and public health research, Dr. Edmund Ndudi Ossai has garnered respect from academic, clinical, and governmental circles. While not all of his accolades may be publicly listed, the recognition of his work in influential studies such as the Truenat implementation speaks volumes. Being a lead investigator on a national-level study involving over 56,000 samples places him in the top tier of Nigeria’s TB researchers. His affiliations with prestigious institutions like Ebonyi State University and his collaborations with global health entities signal the esteem in which he is held. Tuberculosis remains a pressing issue, and contributors like Dr. Ossai are celebrated not just for publishing results, but for providing real solutions. The study he authored has already influenced training, policy, and practice—tangible outcomes that serve as their own form of recognition. His work has likely inspired a new generation of public health professionals who see research not just as academic output, but as a tool for systemic transformation. In the battle against Tuberculosis, Dr. Ossai’s research has earned him the role of a thought leader and innovator.

LEGACY AND FUTURE DIRECTIONS 🚀 | ADVANCING TUBERCULOSIS SOLUTIONS

Looking ahead, Dr. Edmund Ndudi Ossai’s legacy is poised to expand through ongoing research and policy engagement in Tuberculosis diagnostics. His foundational work with Truenat testing has set the stage for larger, more sophisticated investigations into diagnostic reliability and field-level operationalization. With Nigeria planning to scale up the Truenat platform, Dr. Ossai’s insights will be crucial in minimizing diagnostic errors and improving turnaround time. His legacy will also be cemented through future revisions of the Truenat training curriculum, a key recommendation from his study. Moreover, his influence may extend into digital health integration, where mobile data capture and remote machine monitoring could further reduce TB diagnostic delays. Tuberculosis control is evolving, and Dr. Ossai’s future role might include developing national guidelines, mentoring emerging researchers, and participating in global TB eradication initiatives. His ability to translate field data into actionable strategies ensures that his legacy isn’t static—it’s a growing force in public health. For communities long burdened by Tuberculosis, the long-term impact of Dr. Ossai’s work represents hope, innovation, and sustained progress toward eradication.

NOTABLE PUBLICATION

  • Title: Prevalence of hypertension and associated factors among residents of Ibadan-North Local Government Area of Nigeria
    Authors: IO Ajayi, IO Sowemimo, OM Akpa, NE Ossai
    Journal: Nigerian Journal of Cardiology

  • Title: Specialty preferences among final year medical students in medical schools of southeast Nigeria: need for career guidance
    Authors: EN Ossai, KA Uwakwe, UC Anyanwagu, NC Ibiok, BN Azuogu, N Ekeke
    Journal: BMC Medical Education

  • Title: Retention in care and adherence to HIV and AIDS treatment in Anambra State Nigeria
    Authors: CD Umeokonkwo, CA Onoka, PA Agu, EN Ossai, MS Balogun, et al.
    Journal: BMC Infectious Diseases

  • Title: Predictors of practice of breast self-examination: A study among female undergraduates of Ebonyi State University, Abakaliki, Nigeria
    Authors: EN Ossai, BN Azuogu, IO Ogaranya, AI Ogenyi, DO Enemor, MA Nwafor
    Journal: Nigerian Journal of Clinical Practice

  • Title: Physician burnout in Nigeria: a multicentre, cross-sectional study
    Authors: ADG Nwosu, EN Ossai, UC Mba, I Anikwe, R Ewah, BO Obande, et al.
    Journal: BMC Health Services Research

Hanzhen Qiao – Hepatitis – Best Research Article Award

Posted on by Infectious

Hanzhen Qiao - Hepatitis - Best Research Article Award

Henan University of Technology - China

AUTHOR PROFILE

SCOPUS

EARLY ACADEMIC ROOTS 🌱

Dr. Qiao Hanzhen’s academic foundation was rooted in a passion for food science and biotechnology. He laid the groundwork for his research career with advanced degrees, culminating in a Ph.D. that emphasized biochemical and functional food components. From his early educational experiences, Dr. Qiao demonstrated a strong curiosity about the natural healing potential of traditional Chinese ingredients. This intellectual pursuit paved the way for exploring herbal remedies not only for nutritional benefits but also for their pharmacological applications in managing chronic illnesses like Hepatitis. The intersection of natural compounds and liver health became a subtle yet significant thread in his early studies. His educational background is emblematic of a broader scientific movement aiming to bridge Eastern medicinal knowledge with modern biomedical science. During his formative academic years, he gained the analytical tools to investigate complex biological interactions and gained exposure to research methodologies that would later become central to his work on Chinese herbal extracts. These skills equipped him to contribute to new approaches in supporting hepatic functions through dietary interventions. By embedding his early learning in multidisciplinary research, Dr. Qiao built a robust academic identity, positioning him well for impactful contributions to the study and treatment of conditions such as Hepatitis.

PROFESSIONAL ENDEAVORS & LEADERSHIP 👨‍🏫

Currently an Associate Professor at Henan University of Technology, Dr. Qiao Hanzhen has steadily risen as a formidable academic leader. As a Master's Supervisor and Young Backbone Teacher of Henan Province, he mentors students across disciplines, fostering innovation in food science and natural product development. His extensive participation in academic committees—including the Feed Branch of the China Cereals, Oils and Foodstuffs Association and the Henan Feed Industry Association—demonstrates his active role in shaping national food and feed policies. Under his leadership, more than ten key projects have been successfully implemented, reflecting his credibility and expertise. His role in provincial and national research schemes reflects a growing interest in sustainable feed development and the health implications of dietary additives. Among his targeted areas is the effect of herbal bioactives on liver function and immunity, tying directly into therapeutic research involving Hepatitis. Dr. Qiao’s leadership transcends teaching, serving as a bridge between theoretical research and practical applications. His research labs often serve as testing grounds for plant-based innovations, some with promising hepatoprotective outcomes. These initiatives contribute to a broader vision: enhancing health through nutritional interventions, particularly for chronic diseases like Hepatitis, by building better scientific frameworks for herbal efficacy.

RESEARCH FOCUS ON HERBAL EXTRACTS & FUNCTIONAL FOODS 🌿

At the core of Dr. Qiao Hanzhen’s scholarly contributions is a dedicated focus on Chinese herbal extracts and their functional evaluation. His work investigates the bioactive compounds present in native botanicals and their potential roles in enhancing human health, especially in modulating liver function and immunity. His projects span a variety of herbs traditionally used in Chinese medicine, aimed at supporting bodily resilience against oxidative stress and inflammation. One recurring application of these studies is their relevance to hepatology. Hepatitis, being a liver-centered condition, often demands supportive therapies that mitigate liver damage—an area where herbal-based interventions have shown increasing promise. Dr. Qiao’s lab has examined the antioxidant, anti-inflammatory, and detoxifying properties of numerous plant extracts, some of which display potential as adjunct therapies for Hepatitis management. These functional foods are not merely nutritional; they possess properties that may influence biological pathways related to hepatic health. His interdisciplinary research integrates elements of pharmacognosy, nutritional biochemistry, and food technology. The innovative edge lies in using these herbs in feed additives, supplements, or functional beverages, thus expanding the scope of preventive health. Dr. Qiao's focused commitment to herbal science situates him as a leader in researching novel methods to address liver diseases, including Hepatitis.

CONTRIBUTIONS TO NATIONAL & INTERNATIONAL RESEARCH 🌍

Dr. Qiao Hanzhen has made significant contributions to both national and international scientific communities through collaborative research and scholarly publications. He has led or participated in over ten major projects, including prestigious grants under the National Key R&D Program of China’s 14th Five-Year Plan. His involvement in such high-level initiatives indicates both his technical competence and strategic vision. These programs often integrate research themes focused on public health, feed safety, and plant-derived therapeutic agents—some explicitly addressing inflammatory liver conditions like Hepatitis. His work has appeared in respected journals such as Food Chemistry and Antioxidants, reflecting peer recognition across scientific domains. With over 30 peer-reviewed publications, Dr. Qiao has built a body of literature that supports the clinical relevance of natural products. He is a co-author of seven textbooks and has developed two national standards, setting guidelines that may impact future food or herbal product regulation. His research outputs consistently emphasize the importance of evidence-based use of herbs in mitigating conditions such as Hepatitis. By marrying fundamental research with applied science, he continues to influence how we perceive traditional remedies in modern contexts, ensuring their credible inclusion in future therapeutic discussions—especially for hepatic disorders like Hepatitis.

PATENTS, TEXTBOOKS & TECHNICAL ADVANCEMENTS 📘

Innovation forms the backbone of Dr. Qiao Hanzhen’s academic ethos, as reflected in his intellectual property contributions and technical publications. He has filed six patents, one of which has been granted, showcasing novel methodologies or compounds related to herbal extract formulations. These inventions often revolve around natural feed additives or functional food ingredients that may support liver metabolism or possess anti-inflammatory benefits. In parallel, Dr. Qiao has co-authored seven textbooks, serving as essential references for students and professionals in food science, herbal pharmacology, and biotechnology. These educational resources include knowledge drawn from his work on botanical agents and their role in preventing or alleviating diseases like Hepatitis. His national standards development further amplifies his impact, translating research findings into practical, regulated applications. These contributions serve not only academic purposes but also industrial, offering scientifically validated models for herbal product formulation. His technical achievements ensure that the next generation of researchers and practitioners can build upon validated knowledge frameworks, especially in contexts where hepatic health and Hepatitis prevention are public health priorities. Through these enduring academic outputs, Dr. Qiao secures his position as both a knowledge creator and a systems innovator.

RECOGNITION & SCIENTIFIC ACCLAIM 🏅

Recognition for Dr. Qiao Hanzhen’s pioneering work has come through prestigious accolades, most notably the First Prize of the Henan Province Science and Technology Achievement Award. This honor reflects peer and governmental acknowledgment of his sustained contributions to research and societal advancement. The award recognizes his innovation in applying Chinese herbal extracts to improve both feed efficiency and public health—a dual benefit especially relevant in areas grappling with food security and chronic diseases. Among these diseases, Hepatitis figures prominently due to its global prevalence and demand for long-term, non-toxic management strategies. Dr. Qiao’s reputation has also grown through active participation in professional associations, enabling policy engagement and research dissemination. His recognition extends beyond borders through collaborations and citations in international research. Such acclaim has strengthened the visibility of his work on hepatic health and botanical interventions. As the world increasingly turns to integrative approaches for disease management, awards like these endorse Dr. Qiao’s research path as both visionary and practical. They affirm the significance of natural solutions in modern health crises, including the pressing need for innovative adjunct treatments for Hepatitis using food-based and botanical interventions grounded in empirical evidence.

FUTURE DIRECTIONS & LASTING LEGACY 🔬

Looking forward, Dr. Qiao Hanzhen’s legacy is poised to influence both academic and clinical landscapes. His future directions involve expanding the use of Chinese herbal extracts into mainstream therapeutic applications, particularly targeting liver-related conditions such as Hepatitis. He envisions a research ecosystem that marries traditional medicinal wisdom with high-throughput screening technologies, enabling the rapid identification of plant-based agents for disease intervention. His mentorship of graduate students ensures the continuation of this research philosophy, embedding sustainability and public health impact into the heart of future scientific inquiry. Additionally, Dr. Qiao plans to refine the molecular mechanisms behind herbal effects on hepatic cells, with the aim of translating these findings into functional food products and dietary supplements. These innovations could one day become complementary therapies for chronic liver ailments, including Hepatitis, offering safer and culturally relevant alternatives to synthetic drugs. His work also sets the stage for more interdisciplinary collaboration between food scientists, medical researchers, and policy makers. Dr. Qiao’s career trajectory and research vision underscore the importance of integrative medicine in future health solutions, establishing a legacy that bridges traditional knowledge and contemporary science—particularly in the enduring fight against Hepatitis.

NOTABLE PUBLICATION

  • Title: Impacts of zinc caproate supplementation on growth performance, intestinal health, anti-inflammatory activity, and Zn homeostasis in weaned piglets challenged with Escherichia coli K88
    Authors: Not specified in your message (likely multiple authors; can be retrieved from the journal site)
    Journal: Journal of Animal Science and Biotechnology
    Year: 2025

 

  • Title: Anti-inflammatory effects of Rehmannia glutinosa polysaccharide on LPS-induced acute liver injury in mice and related underlying mechanisms
    Authors: Not specified in your message
    Journal: Journal of Ethnopharmacology
    Year: 2025

 

  • Title: Andrographolide protects against the intestinal barrier dysfunction and inflammatory response through modulating ETEC virulence factors in a mouse model of diarrhea
    Authors: Not specified in your message
    Journal: Journal of Functional Foods
    Year: 2024